Interleukin-25 is detrimental for recovery after spinal cord injury in mice. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Dooley, Dearbhaile; Lemmens, Evi; Ponsaerts, Peter; Hendrix, Sven
• Is Part Of: Journal of neuroinflammation. Volume 13:Issue 1(2016)
• Page Start: 1
• Page End: 6
• Publication Date: 2016-12
• Subjects: IL-25 -- Type 2 immune response -- Spinal cord injury -- Basso mouse scale -- Locomotor recovery -- Th1 -- Th2; Central nervous system -- Diseases -- Periodicals; Inflammation -- Periodicals; 616.8
• DOI: 10.1186/s12974-016-0566-y
• Languages: English
• ISSNs: 1742-2094

Abstract

Abstract Background The cytokine, interleukin (IL)-25, is thought to be critically involved in inducing a type 2 immune response which may contribute to regeneration after central nervous system (CNS) trauma. We investigated whether applying recombinant IL-25, locally or systemically, in a mouse model of spinal cord injury (SCI) improves functional and histological recovery. Findings Repeated systemic administration of IL-25 did not influence functional recovery following SCI. In contrast, a single local administration of IL-25 significantly worsened locomotor outcome, which was evident from a decreased Basso mouse scale (BMS) score compared with phosphate-buffered saline (PBS)-treated controls. This was accompanied by a significant increase in lesion size, demyelination, and T helper cell infiltration. Conclusions These data show for the first time that IL-25 is either ineffective when applied systemically or detrimental to spinal cord recovery when applied locally. Our findings question the potentialneuroprotective role of IL-25 following CNS trauma.